Patients with concurrent mutations in KRAS and KEAP1/NFE2L2 had a shorter duration of therapy with platinum-based chemotherapy than other patients with KRAS-mutant lung cancer [10]. The gene discussed is KRAS; the disease is lung carcinoma.